Intellectual Property Rights
A long-standing point of contention is India's framework for intellectual property (IP), particularly concerning pharmaceuticals. The U.S. has consistently placed India on its 'Priority Watch List' for IP protection. American pharmaceutical giants argue
that India's patent laws, specifically Section 3(d) of the Patents Act, are too restrictive. This provision prevents 'evergreening'—the practice of extending a patent's life for minor modifications to a drug—by requiring proof of significantly enhanced efficacy for a new patent. While India defends this as a crucial tool to ensure access to affordable medicines and a policy compliant with WTO norms, the U.S. sees it as a deterrent for innovators. Washington has also flagged the absence of data exclusivity provisions and the use of compulsory licensing, which allows local firms to produce patented drugs in the public interest.
Market Access for Agriculture
Agriculture is another highly sensitive area. The U.S. is pushing for greater access for its agricultural exports, including dairy, poultry, and certain crops, by seeking lower tariffs and the removal of non-tariff barriers. However, India has remained steadfast in protecting its vast agricultural sector, where millions of livelihoods are at stake. Farmers' organizations have warned against opening the dairy market to heavily subsidized American products, fearing it would depress domestic milk prices. India’s strict sanitary and phytosanitary (SPS) standards, which regulate food safety and animal and plant health, are often viewed by the U.S. as protectionist measures that block its exports. These conflicting priorities create a significant impasse, as domestic political pressures in India make major concessions on agriculture extremely difficult.
Price Controls on Medical Devices
The pricing of medical devices has become a flashpoint in trade relations. In recent years, India's National Pharmaceutical Pricing Authority (NPPA) imposed price caps on crucial devices like coronary stents and knee implants to make them more affordable for patients. This move led to a substantial reduction in prices. U.S. medical technology firms, which are major suppliers to the Indian market, argue that these price controls do not account for innovation or quality differences and discourage them from introducing advanced technology in the country. The U.S. government has actively advocated against the expansion of these price controls, framing it as an issue of market access.
The Data Localization Dilemma
In the digital economy, the cross-border flow of data is paramount. However, India has moved towards data localization, which mandates that certain types of data collected from Indian users must be stored within the country's geographical boundaries. From a security standpoint, India sees this as necessary for protecting citizens' privacy and enabling law enforcement access. However, U.S. tech companies and the U.S. government view these requirements as a significant trade barrier. They argue that such rules increase operational costs, disrupt global business models built on centralized data processing, and could lead to a 'splintering' of the internet without necessarily enhancing data security.
Divergent Standards and Certification
A less headline-grabbing but equally important barrier involves differing national standards and certification processes. U.S. exporters often face challenges when India-specific standards are mandated for products, including for information and communication technology (ICT) goods. These requirements can increase compliance costs and time-to-market for American companies. The U.S. has been pushing for India to accept U.S.-developed or international standards as equivalent, which would streamline trade. Resolving these differences over product standards and testing requirements is a key part of ensuring a smoother flow of goods between the two nations.
